数字版emPHasis-10在肺动脉高压中的可比性、可接受性与纵向依从性
该研究评估了基于应用程序的数字版emPHasis-10患者报告结局工具在肺动脉高压患者中的有效性、长期依从性和可接受性。结果表明该工具具有有效性、较好的长期依从性及患者高可接受性评分。
要点
- 数字版emPHasis-10是一种基于应用程序的患者报告结局工具
- 该工具在肺动脉高压患者中显示出有效性
- 患者对该数字工具的可接受性评分较高
核心结论
- 数字版emPHasis-10在肺动脉高压患者中具有有效性、较好的长期依从性和高可接受性。
主要发现
- 数字版emPHasis-10显示出有效性、较长期的依从性以及来自患者的高可接受性评分。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Digital emPHasis-10 is an app-based patient-reported outcome measure for trial or clinical use by patients with pulmonary hypertension. This letter demonstrates this novel tool's validity, longer-term adherence and high acceptability scores from patients. https://bit.ly/4lZiXkE Pulmonary hypertension (PH) affects 1% of the global population and significantly impacts health-related quality of life (HRQoL) [1, 2]. Patient-reported outcome measures (PROMs) are standardised tools used in clinical practice and research to assess health outcomes from the patient's perspective. Routine measurement of HRQoL is supported by clinical guidelines, which recommend disease-specific PROMs [1]. EmPHasis-10 is a widely used 10-item PROM developed for patients in any World Health Organization (WHO) PH group [2, 3]. Available in numerous languages, it has strengths in both its psychometric properties and feasibility [2, 4]. However, it is currently only available in a paper-based format.
引用
- Newman J, Varian F, Hitchcock F, et al. Comparability, acceptability and longitudinal adherence with digital emPHasis-10 in pulmonary arterial hypertension. Eur Respir J. 2025. PMID: 40404213. doi:10.1183/13993003.00198-2025
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。